3-Azido-8-methyl-8-azabicyclo[3.2.1]octane

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: 3-Azido-8-methyl-8-azabicyclo[3.2.1]octane
• 英文别名: 3-azido-8-methyl-8-azabicyclo[3.2.1]octane
• 化学式: C8H14N4
• 分子量: 166.22
• InChiKey: DGQGIIUEBHRECC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  17.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• USE OF THE STAUDINGER LIGATION IN IMAGING AND THERAPY END KITS FOR IMAGING AND THERAPY
  申请人：Koninklijke Philips Electronics N.V.

  公开号：EP1799273A2

  公开（公告）日：2007-06-27
• TARGETED IMAGING AND/OR THERAPY USING THE [3+2]-AZIDE-ALKYNE CYCLOADDITION
  申请人：Koninklijke Philips Electronics N.V.

  公开号：EP2026840A2

  公开（公告）日：2009-02-25
• Targeted Imaging and/or Therapy Using the Staudinger Ligation
  申请人：Robillard Marc Stefan

  公开号：US20080181847A1

  公开（公告）日：2008-07-31

  The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the Staudinger ligation, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural/biological targeting constructs (i.e. biotin/streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations.
• Targeted Imaging And/Or Therapy Using The [3+2] Azide-Alkyne Cycloaddition
  申请人：Robillard Marc Stefan

  公开号：US20080267878A1

  公开（公告）日：2008-10-30

  The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the [3+2] cycloaddition, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural/biological targeting constructs (biotin/streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations.
• [EN] TARGETED IMAGING AND/OR THERAPY USING THE STAUDINGER LIGATION<br/>[FR] IMAGERIE ET/OU THERAPIE CIBLEE COMPRENANT L'UTILISATION D'UNE LIGATION DE STAUDINGER
  申请人：KONINKL PHILIPS ELECTRONICS NV

  公开号：WO2006038185A2

  公开（公告）日：2006-04-13

  The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the Staudinger ligation, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural/biological targeting constructs (i.e. biotin/streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations.